Acumen Pharmaceuticals, Inc. — Director's Dealing 2021

Jul 1, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Acumen Pharmaceuticals, Inc. (ABOS)
CIK: 0001576885
Period of Report: 2021-06-30

Reporting Person: Hardie Robert D. (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A-1 Preferred Stock	$		Common Stock (1124830)		Indirect
Series B Preferred Stock	$		Common Stock (2076326)		Indirect

Footnotes

F1: Each share of Series A-1 Preferred Stock and each share of Series B Preferred Stock will automatically convert into one share of Common Stock of the Issuer upon the closing of the Issuer's initial public offering. The Series A-1 Preferred and the Series B Preferred Stock have no expiration date.

F2: Consists of 562,415 shares of common stock issuable upon conversion of Series A-1 preferred stock held by H7 Holdings LLC, and 562,415 shares of common stock issuable upon conversion of Series A-1 preferred stock held by Level One Partners, LLC. Robert D. Hardie is the Manager of both H7 Holdings, LLC and Level One Partners, LLC and has the power to vote or dispose of the shares held by each entity. The Reporting Person disclaims beneficial ownership of the shares held by H7 Holdings, LLC and Level One Partners, LLC, except to the extent of his pecuniary interest therein.

F3: Consists of 1,038,163 shares of common stock issuable upon conversion of Series B convertible preferred stock held by H7 Holdings LLC, and 1,038,163 shares of common stock issuable upon conversion of Series B convertible preferred stock held by Level One Partners, LLC. Robert D. Hardie is the Manager of both H7 Holdings, LLC and Level One Partners, LLC and has the power to vote or dispose of the shares held by each entity. The Reporting Person disclaims beneficial ownership of the shares held by H7 Holdings, LLC and Level One Partners, LLC, except to the extent of his pecuniary interest therein.